Overall Survival Data in mCRPC
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases
a) Progression free and b) overall survival probability of patients... | Download Scientific Diagram
Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors | SpringerLink
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate | Prostate Cancer and Prostatic Diseases
A-C) Overall survival of 68 patients with metastesis castration... | Download Scientific Diagram
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer - Annals of Oncology
Clinical Parameters Predict Overall Survival in mCRPC | PracticeUpdate
Association between CTC AR-V7 and overall survival in mCRPC. A total... | Download Scientific Diagram
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry | Prostate Cancer and Prostatic Diseases
Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer
Model Simplifies mCRPC Patient Prognoses - Renal and Urology News
Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience | Radiation Oncology | Full Text
Overall survival and second primary malignancies in men with metastatic prostate cancer
Visceral Metastases and Prostate Cancer Treatment: 'Die Hard,' 'Tough Neighborhoods,' or 'Evil Humors'?
a Progression-free survival of 63 Japanese patients with... | Download Scientific Diagram
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial - Annals of Oncology
ASCO GU 2020: Treatment of Chemotherapy-Naïve mCRPC Using Abiraterone Acetate with or without Cabazitaxel
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial - European Urology
View Image
Overall Survival (OS) for mCRPC patients treated with docetaxel for a... | Download Scientific Diagram
Advances in Treating mCRPC: Focus on Immunotherapy
